Posted by Michael Wonder on 20 Mar 2024
Spevigo approved for expanded indications in China and the US
19 March 2024 - The US FDA’s approval expands the use of Spevigo to include the treatment of generalised pustular psoriasis in adults and paediatric patients aged 12 and above weighing ≥40 kg, making it the first targeted therapy that addresses the need for acute and chronic treatment for GPP patients.
Boehringer Ingelheim today announced that the US FDA has approved Spevigo (spesolimab-sbzo) injection for the treatment of generalised pustular psoriasis in adults and paediatric patients aged 12 and above weighing ≥40 kg.
